ELVElevance Health
Price
+33%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market with it.
Elevance Health and its direct and indirect subsidiaries, referred to throughout this document as “we,” “us,” “our,” the “Company” or “Elevance Health,” is a leading health company bringing together the concepts of elevate and advance. We are focused on enhancing well-being and advancing health outcomes by delivering integrated, whole health solutions across the care journey. We support consumers throughout their full health journeys with medical, pharmacy, and behavioral health services designed to address their whole health needs.
In the company’s own words · 10-K filed Feb 6, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Elevance Health (ELV) reported revenue of $50.5B in Q2 2026 (quarter ended Jun 30, 2026), up 1.4% from the same quarter a year earlier. That came with a gross margin of 89% and net income of $1.46B (2.9% of revenue). For the full year FY2025, revenue was $199.1B (+12% year on year) and net income $5.66B. Its largest segment in Q2 2026 was Reportable at $50.5B, 89% of the disclosed total, well ahead of Carelon Rx at 11%. The next results filing is expected around Oct 20, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Mar 2, 2026Regulation FD Disclosure On February 27, 2026, Elevance Health, Inc. (the “Company”) was notified by the Centers for Medicare & Medicaid Services (“CMS”) of its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company’s Medicare Advantage-Prescription Drug (“MA-PD”) …Other event · Form 8-K
- Feb 26, 2026On February 26, 2026, Elevance Health, Inc. (the “Company”) announced certain management changes. Among these changes, Peter D. Haytaian will transition from his role as Executive Vice President and President of Carelon, effective May 4, 2026, to devote more time to family commitments.Director or officer change · Form 8-K
- Dec 10, 2025On December 10, 2025, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) elected Amy W. Schulman to serve as an independent director effective January 12, 2026, with a term expiring at the Company’s 2028 annual meeting of shareholders.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $56.74BThe company’s own SEC segment disclosure.
- Reportable$50.47B89%
- Carelon Rx$6.26B11%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Healthcare
Ranks #17 of 446 by RyuScore